

10/536982

MUM 03/01015

09 DEC 2003

PA 1090533



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

November 10, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/429,564

FILING DATE: November 29, 2002

REC'D 07 JAN 2004

WIPO PCT

PRIORITY DOCUMENT  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

*W. Montgomery*  
W. MONTGOMERY

Certifying Officer

Best Available Copy

60429564.1129027/prov

Please type a plus sign (+) inside this box →

PTO/SB/19 (8-00)  
 Approved for use through 10/31/2002. OMB 0851-0032  
 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 no persons are required to respond to a collection of information unless it displays a

Under the Paperwork Reduction Act of 1995, no  
 valid OMB control number.

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

INVENTOR(S)		Residence
Given Name (first and middle (if any))	Family Name or Surname	(City and either State or Foreign Country)
Shlomo Gavriel	Lewkowicz Meron	Kiryat Tivon 36031, Israel Petach Tikva 49556, Israel
<input type="checkbox"/> Additional inventors are being named on the <sup>A</sup> separately numbered sheets attached hereto		
TITLE OF THE INVENTION (280 characters max)		
METHOD, DEVICE, AND SYSTEM FOR IN VIVO DIAGNOSIS		
CORRESPONDENCE ADDRESS		
Direct all correspondence to:		Place Customer Number Bar Code Label here
<input type="checkbox"/> Customer Number		
OR		Type Customer Number here
<input checked="" type="checkbox"/> Firm or Individual Name Eitan, Pearl, Latzer & Cohen Zedek, LLP.		
Address 10 Rockefeller Plaza		
Address Suite 1001		
City New York	State New York	ZIP 10020
Country USA	Telephone 212-632-3480	Fax 212-632-3489
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification Number of Pages 19		<input type="checkbox"/> CD(s), Number
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets 4		
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		<input checked="" type="checkbox"/> Other (specify) postcard
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)		
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		FILING FEE AMOUNT (\$)
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		05-0649 160
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input checked="" type="checkbox"/> No.		
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:		

Respectfully submitted,

Date 29 / Nov / 2002

SIGNATURE

REGISTRATION NO.  
(if appropriate)

37,912

TYPED OR PRINTED NAME Caleb Pollack

Docket Number:

P-4433-USP

TELEPHONE 212-632-3480

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.54. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Provisional Application, Assistant Commissioner for Patents, Washington, D.C., 20231.

11/29/02

J1129 U.S. PTO

J-672 U.S. PTO

60/429564

02/06/11

P-4433-USP

**United States Provisional Patent Application For:  
METHODS, DEVICE AND SYSTEM FOR IN VIVO DIAGNOSIS**

**FIELD OF THE INVENTION**

The present invention relates to in vivo diagnosis. More specifically, the invention relates to optically based methods, devices and systems for detection of pathologies or other medical conditions in body lumens, for example, in the gastrointestinal (GI) tract.

**BACKGROUND OF THE INVENTION**

Pathologies of the GI tract (which may consist for example of the pharynx, esophagus, stomach, duodenum, small bowel, and colon), include, among others, esophageal carcinoma (e.g., Barrett's esophagus), peptic ulcer diseases, colorectal carcinoma and inflammatory bowel diseases (e.g., ulcerative colitis and Crohn's disease). Early pancreatic cancer may manifest itself through neoplasms released into the small intestine by the pancreas. Gastric cancer is a major cause of death worldwide especially in developing countries. The major type of gastric cancer is adenocarcinoma, which can be further categorized into an intestinal type and a diffuse type. Intestinal type lesions are frequently ulcerative and occur in the distal stomach more often than the diffuse type. These lesions are associated with a worse prognosis than the intestinal type. Colon and rectal cancers accounts for approximately 20% of all deaths due to malignant disease in the United States. Also, cancer of the pancreas is considered the fifth leading cause of cancer deaths in the United States.

P-4433-USP

Delayed detection of GI tract cancers is a major factor contributing to an overall poor prognosis. Signs of early stages of GI tract cancers may be vague and nonspecific. The deep anatomical location of organs and parts of the GI tract may also add to the low yield of early detection. Often, gastrointestinal neoplasms arise in premalignant lesions which are only partially accessible or visible by regular endoscopy or laparoscopy.

Among known modalities used to distinguish normal from malignant tissue, are optically based techniques such as photodynamic diagnosis (PPD), also known as fluorescence diagnosis, and vital staining techniques, such as chromoendoscopy. These techniques are based on specific accumulation of administered agents, such as photosensitizers (in PPD) or pigments (in chromoendoscopy). Photosensitizers (PS) typically selectively concentrate in tumor cells, remaining inactive until exposed to light of a specific wavelength. When light of the specific wavelength is delivered to the PS containing cells, it causes fluorescence of the PS. Vital stains identify specific epithelial cells or cellular constituents by preferential diffusion, absorption or adhesion across the cell membrane.

These techniques are used in various medical fields. PDD, for example, is an established diagnostic tool in urology for the visualization of bladder lesions. In gastroenterology the technique is used to distinguish between low grade and high grade dysplasias and precancerous lesions for example, in Barrett's esophagus and in the colon. Chromoendoscopy is also used mainly for detection of Barrett's esophagus. In these cases the tissues in the different body lumens are examined by an endoscope.

Endoscopic examinations are typically expensive and stressful for patients, leading to very low patient compliance and to low yield of early detection. Additionally, a large part of the GI tract (for example, most of the small intestine) is inaccessible to endoscopes. Thus,

P-4433-USP

endoscopic examinations provide only a partial answer to the needs of early detection and they are not perceived as beneficial in wide scale screening for cancers.

There is thus a need for a patient friendly diagnostic tool, capable of screening even the difficult to reach parts of body lumens, for early signs of cancer.

### SUMMARY OF THE INVENTION

According to embodiments of the invention optically based techniques are used to facilitate the difference between normal and pathological (e.g., malignant) cells in a body lumen. Embodiments of the invention relate to a typically non-invasive autonomous ingestible device, which enables in situ visualization and detection of, for example, neoplastic or malignant or damaged cells or tissue even in areas that are inaccessible to endoscopes.

In one embodiment, a system is provided for diagnosing malignancy in the GI tract. The system, according to one embodiment, includes a composition comprising a marking agent and a pharmaceutically acceptable carrier. Also included in the system is an ingestible device capable of illuminating an in vivo tissue and capable of detecting remitted light from the in vivo tissue. According to an embodiment of the invention the in vivo device may include, for example, a transmitter, typically a wireless transmitter, for transmitting data to a receiving unit that is located externally to the patient.

According to embodiments of the invention a marking agent may include, for example, molecules or compounds that selectively and/or differentially adhere to dysplasias in endo luminal tissues. According to another embodiment a marking agent may include

P-4433-USP

targeting agents, such as antibodies. According to one embodiment the targeting agents are appended to a dye.

A method for detection of dysplasias and/or neoplasms and/or malignancies in the GI tract, according to an embodiment of the invention, includes the step of administering to a person a marking agent, typically by administering a composition comprising a marking agent and a pharmaceutically acceptable carrier, and the step of illuminating the GI tract walls and detecting remitted light. Typically this is performed by inserting to a body lumen, e.g., the GI tract, typically by swallowing, a device for illuminating the GI tract walls and for detecting remitted light. According to one embodiment the device may be an in vivo imaging capsule. According to some embodiments of the invention a patient may be subject to preparation procedures and/or patient positioning procedures.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a block diagram schematically illustrating a system according to an embodiment of the invention;

Figure 2 shows a schematic illustration of an in vivo diagnosing device according to an embodiment of the invention;

Figures 3A and 3B are flowcharts depicting methods of detecting pathologies or conditions, according to different embodiments of the invention.

P-4433-USP

**DETAILED DESCRIPTION OF THE INVENTION**

In the following description, various aspects of the invention will be described. For purposes of explanation, specific configurations and details are set forth in order to provide a thorough understanding of the invention. However, it will also be apparent to one skilled in the art that the invention may be practiced without the specific details presented herein. Furthermore, well-known features may be omitted or simplified in order not to obscure the invention.

Embodiments of the invention are based on specifically staining, for example, neoplastic, malignant or damaged cells or tissue. Other cells or conditions may also be stained according to embodiments of the invention. For example, the term "damaged cells or tissue" may include, for example, infectious or inflammatory lesions, a non-tumorous or noninfectious inflammation, clots, hyperplasia, atherosclerotic plaques and other pathologies.

A system for in vivo diagnosis, according to an embodiment of the invention is schematically illustrated in Fig. 1. The system 100 typically includes a marking agent 12, an in vivo imaging device 14 and a receiving unit 16. The marking agent 12 is typically contained in a composition 122, which comprises a pharmaceutically acceptable carrier 124. According to an embodiment of the invention the composition 122 is introduced into a patient's body lumen in which the marking agent 12 (and possibly the carrier 124) typically migrate to the lumen wall. The imaging device 14 is also introduced into the patient's body lumen and images of the body lumen environment may be obtained. The obtained image data is transmitted to a typically external receiving unit 16 for further analysis and diagnosis. Receiving unit 16 may include image processing capabilities. According to some

P-4433-USP

embodiments image processing takes place either prior to or after the image data is transmitted to the receiving unit.

The marking agent 12 typically contains molecules or compounds that may be optically visible and which selectively and/or differentially adhere to dysplasias in endoluminal tissues. The term dysplasias may be understood to include, inter alia, neoplasms, lesions and/or malignancies.

According to one embodiment, marking agent 12 includes photosensitizers such as 5-aminolevulinic acid (5-ALA). Photosensitizers can be activated by light of a specific wavelength to emit light of a different wavelength. 5-ALA, for example, is a natural precursor of the heme biosynthetic pathway and it induces formation of protoporphyrin IX (PPIX), an endogenous photosensitizer. Application of 5-ALA leads to intracellular accumulation of endogenous PPIX in areas of high grade dysplasias and malignant lesions.

According to another embodiment marking agent 12 may include substances known as vital stains, such as, for example, methylene blue, indigo carmine, Lugol iodine and toluidine blue. Vital stains may include, for example, absorptive stains, which typically identify specific epithelial cells or cellular constituents by preferential diffusion or absorption across cell membranes, and contrast staining which typically highlights tissue topography accentuating irregularities in surface contours. A pharmaceutically acceptable carrier 124 may include, for example, high molecular weight molecules that are typically not absorbed by the stomach. These may include, for example, gelatinous substances and/or other proteins. According to yet another embodiment the marking agent 12 may include, for example, tumor marker targeted molecules. Tumor markers are molecules occurring in blood or tissue that are associated with cancer. Typically, tumor markers are products of



P-4433-USP

cancerous cells or the cells themselves and they represent aberrant production of what may be a typically normal element. Some markers are produced in response to the presence of cancer, such as antibodies. Tumor marker targeted molecules typically have a high affinity to tumor markers and, under certain conditions, will adhere to tumor markers in a liquid environment. These may include, for example, antigens having specificity to tumor marker antibodies. Alternatively, tumor marker targeted molecules may include, for example, antibodies specific to tumor marker antigens. According to an embodiment of the invention a tumor marker targeted molecule may be modified to include a dye or fluorescent moiety.

The composition 122 may be in the form of a powder, tablet, pill, suspension, liquid, spray or any other suitable form for administering the marking agent 12 to the endoluminal walls.

According to an embodiment of the invention the in vivo imaging device 14 may be an ingestible capsule which may include an illumination source (not shown) for illuminating a body lumen, typically the GI tract, an image sensor (not shown) for obtaining images of the body lumen and a transmitter (not shown) for transmitting image or other data to the receiving unit 16. Receiving unit 16 is typically located outside a patient's body and may include an antenna or antenna array (not shown), for receiving image and possibly other data from the device 14, a receiver storage unit, for storing image and other data, a data processor, a data processor storage unit, and an image monitor (not shown), for displaying, *inter alia*, the images transmitted by the device 14 and recorded by the receiving unit 16. Typically, the receiver and receiver storage unit are small and portable, and may be worn on the patient's body during recording of the images. Typically, data processor, data processor storage unit and monitor are part of a personal computer or workstation, which

P-4433-USP

may include standard components such as a processor, a memory, a disk drive, and input-output devices, although alternate configurations are possible. In alternate embodiments, the data reception and storage components may be of another configuration. Processing capabilities, for example for processing real image data and fluorescent data, may be included in the receiving unit or in the workstation.

Reference is now made to Fig. 2, which schematically illustrates an in vivo diagnosing device, such as device 14 of Fig. 1, according to an embodiment of the invention. In an exemplary embodiment, the device 20 is an autonomous capsule shaped device capturing images of a body lumen, typically of the GI tract. Typically, device 20 includes at least one sensor such as an image sensor 24, for capturing images and at least one illumination source 23 (two illumination sources 23 are included in Fig. 2 for illustrative purposes). The image sensor 24 may be a CMOS, CCD or any other suitable in vivo image sensor. An optical dome 21 provides a generally transparent cover for the optical elements, provides a sealed barrier to bodily fluids, and may perform other functions (such as holding optical elements). An optical system 22, including, for example, one or more optical elements, such as one or more lenses or composite lens assemblies, or any other suitable optical elements, may aid in focusing reflected light onto the image sensor 24 and performing other light processing. The device 20 may include a dedicated photodetector 28 and/or a filter 224 which may cover all or some of the pixels of the image sensor 24. Device 20 typically includes a transmitter 26, for transmitting image and possibly other (e.g., non-image) information to a receiving device, and may include other components, such as, for example, a compression module for compressing data. According to one embodiment the transmitter 26 is an ultra low power radio frequency (RF) transmitter with high bandwidth

P-4433-USP

input, possibly provided in chip scale packaging. The transmitter 26 may transmit via an antenna 27. The transmitter 26 may also include circuitry and functionality for controlling the device 20. For example, a master clock included in transmitter 26 may control illumination functions of the device. Typically, the device includes a power source 25, such as one or more batteries. For example, the power source 25 may include silver oxide batteries, lithium batteries, or other electrochemical cells having a high energy density, or the like. Other power sources may be used. Other components and sets of components may be used. For example, the power source may be an external power source transmitting power to the capsule, and a controller separate from the transmitter 26 may be used. Further, other devices and systems for in-vivo imaging may be used, having imaging devices and reception/display systems of other configurations.

According to one embodiment fluorescent dyes are utilized to specifically stain neoplastic and/or malignant cells. Accordingly, the in vivo device 20 may include a plurality of light sources, for example, a white light source for obtaining real images and a blue light source for illuminating (energizing) fluorescent dyes. According to an embodiment of the invention photosensitizing drugs are administered to a patient and after a metabolic period but prior to decline of sensitivity, an imaging device is ingested for obtaining images of practically the entire GI tract. Imaging of the GI tract may be done in a regular mode, in which images are obtained by illuminating typically white light. Imaging may also be done in a fluorescent mode in which light is illuminated in a first wavelength and remitted light of a second wavelength is collected. In an alternative embodiment endo - luminal sites may be illuminated by white light followed by a dark period in which fluorescent emission may be detected. According to yet another embodiment dyes, such as vital stains, are utilized to

P-4433-USP

specifically or differentially stain neoplastic and/or malignant cells. In this embodiment imaging in a regular mode may provide optical information for diagnosing the endoluminal condition.

Referring back to Fig. 2, according to one embodiment, device 20 is swallowed by a patient to whom a photosensitizer or another dye has been administered. Device 20 is swallowed about 4-6 hours after the administration of a photosensitizer or within about 10 minutes after application of a dye such as a vital stain onto the GI tract wall. As the device 20 is swallowed it is activated and illumination source 23, which may be for example a white LED begins to illuminate. Remitted light is focused through optical system 22 onto image sensor 24, or, optionally onto photodetector 28, thereby forming images that are then transmitted by transmitter 26. According to another embodiment activation of the device 20 causes the successive action of a white LED and a monochromatic LED (e.g., a blue LED), for obtaining a real image and a successive fluorescent image. The two images may then be processed, for example by image subtraction, to obtain diagnostic information.

According to one embodiment a patient is administered photosensitizer, such as 5-ALA, which induces the formation of PPIX. PPIX can be induced by violet light to emit red light. In this case device 20 may include at least one illumination source 23 which is a monochromatic light source, for example, in the range of about 400nm. In alternate embodiments light source 23 may include a filter (not shown) such as a bandpass filter for obtaining violet-blue illumination. Capsule 20 may be swallowed by a patient to whom 5-ALA has been administered, and light source 23 may illuminate in violet whereas remitted light in the range of 600 - 800 nm will be detected by dedicated photodetector 28, which may be any light detecting device such as a CCD camera or by image sensor 24 due to filter

P-4433-USP

244 that may be any suitable filter, such as a red filter. In another embodiment illumination source 23 may be controlled (for example by transmitter 26) to illuminate in a flash mode where each flash of light is followed by a dark period. White light or monochromatic light may be used to illuminate the GI tract wall whereas real image frames may be obtained during the illumination period and fluorescent images may be obtained during the dark periods. Any image obtained during the dark period is a result of the delayed fluorescent emission of a photosensitizer or other fluorescent dye. Data obtained from fluorescent images may be indicative of dysplasias or malignancies.

According to another embodiment images of the GI tract wall obtained from a patient to whom a dye, such as methylene blue, has been administered, will be stained blue. Real images of the stained GI tract wall may provide data regarding the staining. Differential staining, for example, absent or inhomogeneous staining in the case of methylene blue, targets possible dysplasia or cancer.

Methods for detecting, for example, malignant and/or damaged cells or tissue, according to different embodiments of the invention are depicted in Figs. 3A and 3B.

According to one embodiment (Fig. 3A) a fluorescent dye is administered to a patient (310). The body lumen wall is then illuminated in a first wavelength (311) and remitted light in a second wavelength is then detected (312). Images of the remitted light in the second wavelength may then be used to diagnose dysplasias of the lumen wall.

A fluorescent dye may be a photosensitizer, for example, as described above. According to another embodiment a fluorescent dye may be a tumor marker targeted -dye complex. According to some embodiments tumor marker targeted molecules may include, for example, antibodies to antigenic determinants associated with cancer, such as, CA19.9.

P-4433-USP

(an antigenic determinant associated with cancers such as pancreas, colorectal and gastric) and CEA (an antigenic determinant associated with cancers such as pancreas, colorectal, liver and gastric). According to other embodiments tumor marker targeted molecules may include, for example, antigenic determinants having affinity to antibodies associated with cancer, such as Gastric Mucin, which is specific to an IgG antibody associated with stomach and colon cancers. Many tumor marker targeted molecules are commercially available, for example, 116-NS-19-9 is a CA19.9 specific antibody and mCEA is a CEA specific antibody, both available from ARUP Laboratories of the Fitzgerald Industries. These molecules may be modified as is known in the art to include a dye moiety. According to some embodiments, through formation of an antibody-antigen complex, a tumor marker targeted molecule is linked to a target cancer cell and will adhere to that cell even after washing of the tissue. A tumor marker targeted molecule carrying a fluorescent dye may then be imaged by being illuminated with a first wavelength and emitting a second wavelength which may be detected, for example, by using appropriate color filters or dedicated photodetectors.

Typically, the marker agents, such as the dyes or target molecules containing dyes, are contained in a pharmaceutical composition. The composition may be formulated to, for example, a tablet or a capsule, a composition for injection, a spray, an aerosol, topical composition, a syrup or any suitable form. In cases where there is more than one composition, each of the compositions can be manufactured in a different form. In another embodiment, the compositions can be manufactured in the same form. The compositions may be administered by any suitable route, for example, by oral application or by direct application during surgery using a laparoscope or trocar. In alternate embodiments a dye

P-4433-USP

containing composition may be sprayed onto a lumen wall by methods known in the art, for example, by use of an endoscope or by use of burst release capsules. Tablets that release active ingredients upon changes in environmental pH or temperature are known and may be utilized according to certain embodiments of the invention.

Compositions according to embodiments of the invention may include a pharmaceutically acceptable carrier. The choice of carrier can be determined in part by the particular dye used, as well as by the particular route of administration of the composition. The carrier is typically compatible with both the dye and the tissues and organs of the patient. Moreover, the carrier typically does not interfere with the energy applied or images obtained following administration.

Other additives may be included in compositions according to embodiments of the invention. Appropriate additives may be selected such that they do not interfere with the activity of the targeted molecule and such that they may facilitate the reaction of the targeted molecule with a tumor marker. In some instances, an additive is selected to increase the specificity, toxicity, solubility, serum stability, and/or intracellular availability of the targeted moiety.

If oral administration is desired, the marking agent should be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. Oral compositions will generally include an inert diluent or an edible carrier and may be compressed into tablets or enclosed in gelatin capsules. For the purpose of oral administration, the active compound or compounds can be incorporated with excipients and used in the form of tablets, capsules or

P-4433-USP

troches. Pharmaceutically compatible binding agents and adjuvant materials can be included as part of the composition.

The step of administering a marker agent to a patient may be preceded by preparation steps, which may include washing the lumen wall, for example by ingesting a volume of water. Other preparation steps may include having the patient fast prior to administration or emptying of lumens, such as the large intestine. The steps of illuminating and detecting remitted light can be performed, for example, as described above by using an in vivo imaging device. Inserting an in vivo device into body lumens may be accompanied by positioning of the patient so as to ensure proper positioning of the device in the lumen and full coverage of the lumen.

Steps of a method according to one embodiment of the invention are illustrated in the Example below.

Note that the various sequences provided are exemplary only, and are not intended to be limiting; other steps or series of steps may be used. Other ranges or amounts may be used, other diagnostic agents, and other configurations for an imaging/display device and system, if suitable.

#### EXAMPLE 1

##### Procedure for PPD using an ingestible imaging capsule

1. A patient after a 12 hour fast is given 0.5 liter water;
2. half an hour later 5-ALA is administered to the patient in the form of a powder of more than 99% purity (commercially available, e.g. from Medac GmbH,



P-4433-USP

Hamburg, Germany). A water/juice solution is prepared at a dose of 15 - 60 mg/Kg body weight, and is orally ingested by the patient;

3. 4-7 hours after oral ingestion the patient ingests 0.5 liter of water to wash the GI tract tissue from excess 5-ALA.
4. 10 minutes after the ingestion of water the patients ingest a Given™ capsule which includes at least one blue LED and a red filter over parts of the CMOS image sensor;
5. Images of the GI tract are obtained in the usual manner (recorded and down loaded to the RAPID™ work station) as well as fluorescent images obtained by the CMOS image sensor. For view of the entire GI tract images are collected for a period of at least 8 hours;
6. Analysis of the images may include comparing white light image frames to consecutive or simultaneous fluorescent image frames.

It will be appreciated that liquids reach the stomach in a matter of minutes, the small intestine in the range of 1-3 hours and the large intestine in about 6 hours. Thus, the timing of the different steps may be adjusted as needed.

According to a second embodiment (Fig. 3B) a vital stain dye is administered to a patient (320). The body lumen wall is then illuminated typically by white light (321) and images of the lumen wall are then obtained (322). The obtained images may then be used to diagnose dysplasias of the lumen wall. Image processing (e.g., color enhancement) capabilities of the imaging device or of its workstation may be utilized.

P-4433-USP

Vital stains that may be used according to embodiments of the invention may include, for example, methylene blue (detailed above), indigo carmine, which is a blue contrast stain and which can accentuate subtle mucosal abnormalities, Lugol iodine solution, which is an absorptive stain with an affinity for glycogen in nonkeratinized squamous epithelium. After administration of Lugol iodine solution normal esophageal mucosa turns a prominent green-brown color within moments, gradually fading over minutes to hours. In this case absence of staining indicates diminished or absent glycogen content, for example, as seen in squamous cell cancers, dysplasia, Barrett epithelium, gastric metaplasia. Toluidine blue may also be used for staining of nuclei, thereby staining tissues having increased mitotic activity.

According to one embodiment an in vivo imaging device having at least one monochromatic illumination source (for example, a blue LED) may be used for better detection of the vital stains. Alternately, color filters may be used for viewing images obtained from the GI tract, for enhancing detection of vital stains.

Steps of methods according to further embodiments of the invention are illustrated in the Examples below.

## **EXAMPLE 2**

### Procedure I for chromo-capsule endoscopy

1. 1% sterile solution of methylene blue is sprayed onto the esophagus mucosa;
2. 10% acetylcysteine (mucolytic agent) is applied to the esophagus mucosa within minutes of the methylene blue application;

P-4433-USP

3. A horizontally positioned patient immediately ingests a Given™ M2A™ capsule;
4. The patient may be slowly rotated;
5. images of the GI tract are obtained in the usual manner (recorded and down loaded to the RAPID™ work station). For view of the entire GI tract images are collected for a period of at least 8 hours.

### EXAMPLE 3

#### Procedure II for chromo-capsule endoscopy

1. 0.5% to 0.8% solution of indigo carmine is sprayed onto the esophagus mucosa;
2. A horizontally positioned patient immediately ingests a Given™ M2A™ capsule which includes at least one blue LED;
3. images of the GI tract are obtained in the usual manner (recorded and down loaded to the RAPID™ work station). For view of the entire GI tract images are collected for a period of at least 8 hours.

It will be appreciated that the positioning and rotating of the patient may enhance positioning and coverage by the capsule of the lumen being inspected. For example, swallowing a capsule while being horizontally positioned ensures the capsule stays in the esophagus for a desired amount of time.

For efficient view of areas such as the esophagus a specifically designed imaging capsule may be used. For example, a capsule having a plurality of optical pathways may be

P-4433-USP

used for obtaining a wide angle of view. Such a capsule is described in WO 02/054932 which is assigned to the common assignee of the present invention and which is hereby incorporated by reference. Alternately, careful positioning of a patient while swallowing an imaging capsule may assist in keeping the imaging capsule in a desired location for obtaining images of the esophagus.

According to some embodiments of the invention there are provided kits for diagnosing malignant or damaged cells or tissues. According to one embodiment a kit may contain at least one composition which comprises a marker agent. According to another embodiment a kit may also contain a typically single use wireless in vivo imaging device.

It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather the scope of the present invention is defined only by the claims, which follow:

P-4433-USP

## CLAIMS

1. A system substantially as described hereinabove.
2. An in vivo device substantially as described hereinabove.
3. A method substantially as described hereinabove.
4. A kit substantially as described hereinabove.



**FIGURE 1**

FIGURE 2



ADMINISTRATION OF FLUORESCENT DYE  
TO A PATIENT (310)




ILLUMINATION WITH FIRST  
WAVELENGTH  
(311)



DETECTION OF REMITTED LIGHT IN  
SECOND WAVELENGTH  
(312)

**FIGURE 3A**



**FIGURE 3B**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**